The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Biomarker analysis and final results of INT70/09 phase II proof-of-concept study of pazopanib (PZP) in refractory urothelial cancer (UC).
Andrea Necchi
Consultant or Advisory Role - GlaxoSmithKline
Nadia Zaffaroni
No relevant relationships to disclose
Luigi Mariani
No relevant relationships to disclose
Lawrence H. Schwartz
No relevant relationships to disclose
Nicola Nicolai
No relevant relationships to disclose
Patrizia Giannatempo
No relevant relationships to disclose
Flavio Crippa
No relevant relationships to disclose
Carlo Morosi
No relevant relationships to disclose
Alessandro M. Gianni
No relevant relationships to disclose
Filippo G. De Braud
No relevant relationships to disclose
Roberto Salvioni
No relevant relationships to disclose